Search results
ImmunityBio immunotherapy shows positive overall survival in lung cancer trial (NASDAQ:IBRX)
Seeking Alpha· 2 weeks agoImmunityBio's immunotherapy drug, Anktiva, shows positive results in a trial for non-small cell lung cancer, boosting shares by 17% premarket.
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 7 days agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
Pharmaceutical Technology via Yahoo Finance· 1 week agoGlobalData is the parent company of Pharmaceutical Technology. Pfizer is also seeking...
Swing Against Cancer 2024 breaks records, raises $220,000 for research
The Desert Sun via Yahoo News· 5 days agoOne name came up repeatedly — Elia Skinner, MD, a former USC Norris Comprehensive Cancer Center...
Biodexa gains license for polyposis asset as stock more than doubles
Pharmaceutical Technology via Yahoo Finance· 1 week agoThe drug won US Food and Drug Administration (FDA) approval...Fyarro will generate $404m by 2030....
FDA grants full approval to cervical cancer drug TIVDAK By Investing.com
Investing.com· 1 week agoFood and Drug Administration (FDA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of...
Project Optimus: helping or hindering cancer drug development?
Clinical Trials Arena via Yahoo Finance· 6 days agoTypically, the agency asks companies to evaluate the dose of a cancer therapy after it has been...
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug
Morningstar· 1 week agoThe companies' drug Tivdak had previously been granted accelerated approval by the U.S. Food and Drug Administration, which allows quicker approval for drugs addressing a ...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 7 days agoPfizer also recently said its new drug, Adcetris, improved overall survival, progression-free ...
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in...
Morningstar· 2 weeks agoFood and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with ...